Oda et al. also reported that BMI ≥ 25.0 was a risk factor for the occurrence of hepatotoxicity in patients with EGFR-mutated NSCLC undergoing gefitinib monotherapy [20], in accordance with the present results. This evidence concerns the gene EGFR and non-small cell lung carcinoma.